$5.79
0.00%
Nasdaq, Aug 30, 01:06 am CET
ISIN
US1374041093
Symbol
CADL

Candel Therapeutics Inc Stock price

$5.79
-0.78 11.87% 1M
-3.19 35.49% 6M
-2.89 33.29% YTD
-0.59 9.25% 1Y
+2.39 70.29% 3Y
-1.21 17.29% 5Y
-1.21 17.29% 10Y
-1.21 17.29% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.03 0.52%
ISIN
US1374041093
Symbol
CADL
Industry

Key metrics

Basic
Market capitalization
$317.8m
Enterprise Value
$224.8m
Net debt
positive
Cash
$100.7m
Shares outstanding
54.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
62.1%
Return on Equity
-83.2%
ROCE
-39.7%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-35.1m | $-37.9m
EBIT
$-36.2m | $-38.2m
Net Income
$-22.1m | $-19.8m
Free Cash Flow
$-29.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-1.2% | -17.1%
EBIT
-1.6% | -14.5%
Net Income
55.7% | 64.2%
Free Cash Flow
3.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.5
Short interest
15.5%
Employees
38
Rev per Employee
$0.0
Show more

Is Candel Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Candel Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Candel Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
11% 11%
-
- Research and Development Expense 20 20
3% 3%
-
-35 -35
1% 1%
-
- Depreciation and Amortization 1.10 1.10
12% 12%
-
EBIT (Operating Income) EBIT -36 -36
2% 2%
-
Net Profit -22 -22
56% 56%
-

In millions USD.

Don't miss a Thing! We will send you all news about Candel Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Candel Therapeutics Inc Stock News

Neutral
GlobeNewsWire
5 days ago
NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will participate in upcoming investor co...
Positive
Proactive Investors
17 days ago
Candel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs. CEP Dr Paul Peter Tak said Candel has had “another very successful quarter”, highlighting that its lead program CAN-2409 achieved its primary endpoint in early localized, newly diagnosed prostate...
Positive
Proactive Investors
19 days ago
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA granted it Regenerative Medicine Advanced Therapy (RMAT) status. The clinical-stage biotech reported a narrower second-quarter loss, backed by stronger trial results and financing that will help suppor...
More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office United States
CEO Paul-Peter Tak
Employees 38
Founded 2002
Website www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today